|Bid||0.0000 x 2200|
|Ask||0.0000 x 2200|
|Day's range||2.3555 - 2.6400|
|52-week range||2.3555 - 15.0000|
|Beta (5Y monthly)||1.84|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2022 - 11 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.29|
BOSTON, November 16, 2021--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the following upcoming virtual investor conferences:
Please be advised that this call is being recorded at Gamida Cell's request. Now, I would like to introduce your host for today's conference, Mr. Josh Hamermesh, chief business officer. Welcome to today's call, during which we will provide an update on the company and review our financial results for the third quarter of 2021.
BOSTON, November 15, 2021--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2021. Net loss for the third quarter of 2021 was $19.6 million, compared to a net loss of $14.8 million for the same period in 2020. As of September 30, 2021, Gamida Cell had total cash and cash equivalents of $120.8 million.